ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

Both drugs target EZH2, a protein that helps control which genes are active or silent. After just 48 hours of drug exposure, the cells began producing insulin and responding to glucose—just like ...

The critical role of EZH2, an essential epigenetic regulator, in cancer progression and treatment is underscored in this new review article published in Genes & Diseases. The study highlights the ...

EZH2, the subunit of PRC2 that carries the H3K27 ... For example, the H3K4me3 histone methyltransferase MLL2 assembles a protein complex containing UTX, which demethylates H3K27me3 (ref.